摘要
目的观察重组人尿激酶原用于急性心肌梗死的疗效并总结护理要点。方法选择2013年1月至12月医院收治的患者100例,随机分为观察组和对照组,各50例。两组患者接受相同辅助治疗后,对照组患者给予尿激酶溶栓治疗,观察组给予重组人尿激酶原溶栓治疗,均给予适当的护理干预。结果溶栓治疗180～300 min后,观察组的血管再通率为82.00%,高于对照组的72.00%（P〈0.05）。治疗后观察组患者心电图ST段完全回落率高于对照组（P〈0.05）,部分回落率则与对照组相当（P〉0.05）。治疗后,两组患者纤溶酶原激活物（t-PA）水平均上升,且观察组上升幅度高于对照组（P〈0.05）;观察组患者人纤溶酶原激活剂抑制物（PAI-1）表达水平较治疗前下降（P〈0.05）,对照组则无显著变化（P〉0.05）,观察组优于对照组（P〈0.05）。与对照组比较,观察组皮下出血、消化道出血发生率均显著低于对照组（P〈0.05）。随访半年,观察组急性心力衰竭发生率为2.00%,显著低于对照组的10.00%（P〈0.05）;再发性心绞痛和急性心肌梗死发生率与对照组相当（P〉0.05）。结论重组人尿激酶原用于急性心肌梗死的溶栓治疗,临床再通率高,能促进心电图ST段回落,同时可促进纤溶系统平衡,减少远期的心脏不良事件。适当的护理干预能降低出血引发的不良后果,降低死亡率,临床用药更安全。
Objective To evaluate the efficacy and safety of thrombolytic therapy with recombinant human prourokinase for patients with acute myocardial infarction. Methods 100 patients with acute myocardial infarction in our hospital from Janury to Dencember 2013 were selected and divided into test group （50 cases） and control group （50 cases） according to the therapeutic methods. Results After 180 - 300 min treatment, the recanalization rate of test group were 82. 00% , higher than 72. 00% of control group（ P〈 0. 05） . The complete ST - segment resolution of test group were significant with control group（ P〈 0. 05）, the part ST - segment resolution of test group were significant with control group（ P〉 0. 05） . The t - PA were rasied in two groups, higher than control group（ P〈 0. 05） . The PAI - 1 in test group were lower than treatment before（ P〈 0. 05）, but no differences in control group（ P〉 0. 05）, better than control group（ P〈 0. 05） . The subcutaneous bleeding, the incidence of gastrointestinal bleeding with the statistically significant betweem test group and control group（ P〈 0. 05） . Follow - up for half a year, the incidence of acute heart failure were 2. 00% in test group, lower than 10. 00% in control group（ P〈 0. 05） . The incidence of recurrent angina and acute myocardial infarction were no significant be-tween two groups（ P〉 0. 05） . Conclusions Thrombolytic therapy with recombinant human prourokinase for patients with acute myocar-dial infarction has advantages of reliable curative effect and high safety, which is worthy of clinical application and promotion.
出处
《中国药业》
CAS
2015年第15期76-78,共3页
China Pharmaceuticals
关键词
重组人尿激酶原
急性心肌梗死
临床疗效
护理
thrombolytic therapy with recombinant human prourokinase
acute myocardial infarction
clinical efficacy
nursing
